Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N. E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter and Göran Karlsson

Published e-Letters

Compose eLetter

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
Publication Date - String
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.

Vertical Tabs

Jump to comment:

  • RE: Differential effects of imatinib and bosutinib on CML progenitor cells
    • Carlo Gambacorti-Passerini, Full Professor in Hematology University of Milano-Bicocca, Dept. of Medicine and Surgery, via Cadore 48, Monza, IT 20900, ASST-Monza, S. Gerardo Hospital
    Warfvinge and colleagues describe the results of single cells analysis in CML patients at diagnosis and during initial treatment with Tyrosine Kinase Inhibitors (TKIs) (1). They document a preferential survival during TKIs treatment of the most primitive cells which do not express cKIT. They suggest that TKIs work preferentially on more mature subpopulations of CML cells because they inhibit both BCR-ABL and cKIT (Our data suggest that TKI treatment, which inhibits both BCR-ABL and cKIT signaling, is most efficient on LSC subpopulations with a high frequency of cKIT+ cells but spares cKIT - quiescent, primitive subpopulations). Since the authors studied patients treated with both imatinib and with bosutinib, which does not inhibit cKIT (2), it would be interesting to know if they noted different behaviors in the patients receiving these two TKIs. If this would not be the case one should then conclude that the Kit inhibitory activity does not play an important role in this phenomenon. References 1. Warfvinge R, Geironson L, Sommarin MNE, et al. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood 2017;129(17):2384-94. 2. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer research 2006;66(23):11314-22.
    Conflict of Interest:
    CGP declares grants from Pfizer.